Flex Nucleic Acid Test Identifies Respiratory Pathogens
By LabMedica International staff writers Posted on 21 Sep 2015 |
Image: The Verigene Test Cartridge designed for multiplex analysis of one patient sample and used with the Verigene System (Photo courtesy of Nanosphere).
The first test of its kind, which features proprietary software, allows the 16 viral and bacterial targets identified by the assay to be reported as a full multiplex panel or in various user-defined subsets.
The proprietary gold nanoparticle chemistry offers highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The system rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus.
Currently, the multiplexed assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy and reduced spread of antibiotic resistance.
The Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) (Nanosphere, Inc.; Northbrook, IL, USA) is for the automated sample-to-result Verigene System and has received US Food and Drug Administration (FDA; Silver Springs, MD, USA) 510(k) clearance. Verigene RP Flex joins Nanosphere's growing menu of infectious disease tests, including: Verigene Gram-Positive and Gram-Negative Blood Culture Tests, which identify bacteria and related antibiotic resistance markers associated with bloodstream infections and sepsis; Verigene Enteric Pathogens Test, which identifies bacteria, viruses, and toxins that cause acute gastroenteritis; Verigene Clostridium difficile Test, which identifies C. difficile, the cause of deadly hospital-acquired diarrhea.
Paul Granato, PhD, Professor Emeritus of Pathology at Upstate Medical University (Syracuse, NY, USA), said, “The demand and need for respiratory pathogen testing varies by season, geography, epidemiology and patient demographics. RP Flex is the first respiratory test that provides labs with the flexibility to choose and pay for only the microbial targets applicable to a given patient, which in turn allows them to practice better test stewardship and reduce healthcare costs.”
Related Links:
Nanosphere, Inc.
US Food and Drug Administration
Upstate Medical University
The proprietary gold nanoparticle chemistry offers highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The system rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus.
Currently, the multiplexed assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy and reduced spread of antibiotic resistance.
The Verigene Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) (Nanosphere, Inc.; Northbrook, IL, USA) is for the automated sample-to-result Verigene System and has received US Food and Drug Administration (FDA; Silver Springs, MD, USA) 510(k) clearance. Verigene RP Flex joins Nanosphere's growing menu of infectious disease tests, including: Verigene Gram-Positive and Gram-Negative Blood Culture Tests, which identify bacteria and related antibiotic resistance markers associated with bloodstream infections and sepsis; Verigene Enteric Pathogens Test, which identifies bacteria, viruses, and toxins that cause acute gastroenteritis; Verigene Clostridium difficile Test, which identifies C. difficile, the cause of deadly hospital-acquired diarrhea.
Paul Granato, PhD, Professor Emeritus of Pathology at Upstate Medical University (Syracuse, NY, USA), said, “The demand and need for respiratory pathogen testing varies by season, geography, epidemiology and patient demographics. RP Flex is the first respiratory test that provides labs with the flexibility to choose and pay for only the microbial targets applicable to a given patient, which in turn allows them to practice better test stewardship and reduce healthcare costs.”
Related Links:
Nanosphere, Inc.
US Food and Drug Administration
Upstate Medical University
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia